Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 9/20 | 0.68 |
| ▸ | BRAF | P15056 | 7/20 | 0.64 |
| ▸ | RAF1 | P04049 | 5/20 | 0.64 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.61 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.59 |
| ▸ | MMP13 | P45452 | 1/20 | 0.58 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.57 |
| ▸ | PLK4 | O00444 | 2/20 | 0.56 |
| ▸ | AURKA | O14965 | 2/20 | 0.56 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.56 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.56 |
| ▸ | ABL1 | P00519 | 2/20 | 0.56 |
| ▸ | LCK | P06239 | 2/20 | 0.56 |
| ▸ | FYN | P06241 | 2/20 | 0.56 |
| ▸ | LYN | P07948 | 2/20 | 0.56 |
| ▸ | RET | P07949 | 2/20 | 0.56 |
| ▸ | SRC | P12931 | 2/20 | 0.56 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.56 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.56 |
| ▸ | AXL | P30530 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL177735 | 0.87 | KDR (0.67) | KDRBRAFRAF1EPHX2MAPK14 | |
| SCHEMBL26155567 | 0.87 | KDR (0.67) | KDRBRAFRAF1EPHX2MAPK14 | |
| SCHEMBL5319531 | 0.87 | KDR (0.67) | KDRBRAFRAF1EPHX2MAPK14 | |
| SCHEMBL15545978 | 0.87 | KDR (0.67) | KDRBRAFRAF1EPHX2MAPK14 | |
| SCHEMBL16651380 | 0.87 | KDR (0.67) | KDRBRAFRAF1EPHX2MAPK14 | |
| SCHEMBL6014811 | 0.87 | KDR (0.63) | KDRBRAFRAF1EPHX2MAPK14 | |
| SCHEMBL6014943 | 0.87 | KDR (0.53) | KDRBRAFRAF1EPHX2MAPK14 | |
| SCHEMBL29834825 | 0.87 | KDR (0.63) | KDRBRAFRAF1EPHX2MAPK14 | |
| SCHEMBL26922701 | 0.87 | KDR (0.63) | KDRBRAFRAF1EPHX2MAPK14 | |
| SCHEMBL18681347 | 0.87 | BRAF (0.70) | KDRBRAFRAF1EPHX2MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160264548-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-09-15 | — | — | US | disclosed |
| US-9381177-B2 | Substituted N-(2-arylamino)aryl sulfonamide-containing combinations | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-07-05 | — | — | US | disclosed |
| US-9381177-B2 | Substituted N-(2-arylamino)aryl sulfonamide-containing combinations | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-07-05 | — | — | US | disclosed |
| WO-2015051149-A1 | SORAFENIB ANALOGS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2015-04-09 | — | — | WO | disclosed |
| US-20140329866-A1 | OMEGA-CARBOXYARL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER HEALTHCARE LLC (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140329866-A1 | OMEGA-CARBOXYARL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER HEALTHCARE LLC (US) | 2014-11-06 | — | — | US | disclosed |
| US-8841330-B2 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841330-B2 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2014-09-23 | — | — | US | disclosed |
| EP-1643991-B1 | BENZIMIDAZOLE CARBOXAMIDES AS RAF KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2014-03-12 | — | — | EP | disclosed |
| EP-1641759-B1 | MALONAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-03-12 | — | — | EP | disclosed |
| US-7235576-B1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-06-26 | — | — | US | disclosed |
| US-7235576-B1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-06-26 | — | — | US | disclosed |
| US-20070093532-A1 | Benzimidazole carboxamides as raf kinase inhibitors | MERCK PATENT GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
| US-20070093532-A1 | Benzimidazole carboxamides as raf kinase inhibitors | MERCK PATENT GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
| US-20070093529-A1 | Diacylhydrazine derivatives | MERCK PATENT GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
| US-20070093529-A1 | Diacylhydrazine derivatives | MERCK PATENT GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
| US-20070020704-A1 | Diaryl ureas with kinase inhibiting activity | BAYER HEALTHCARE LLC | 2007-01-25 | — | — | US | disclosed |
| US-20070020704-A1 | Diaryl ureas with kinase inhibiting activity | BAYER HEALTHCARE LLC | 2007-01-25 | — | — | US | disclosed |
| US-20070010560-A1 | angiogenesis, in particular in tumors, restenoses, diabetic retinopathy, macular degenerative disease or rheumatoid arthritis | MERCK PATENT GMBH (DE) | 2007-01-11 | — | — | US | disclosed |
| US-20070010560-A1 | angiogenesis, in particular in tumors, restenoses, diabetic retinopathy, macular degenerative disease or rheumatoid arthritis | MERCK PATENT GMBH (DE) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093532-A1 | Benzimidazole carboxamides as raf kinase inhibitors | BRAF, RAF1, ARAF | KDR 843/4885BRAF 1/4885RAF1 2/4885 |
| US-20160264548-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | BTK, SYK, LCK | KDR 533/4885BRAF 78/4885RAF1 352/4885 |
| US-20070010560-A1 | angiogenesis, in particular in tumors, restenoses, diabetic retinopathy, macular degenerative disease or rheumatoid arthritis | BRAF, RAF1, VEGFA | KDR 4/4885BRAF 1/4885RAF1 2/4885 |
| US-20070020704-A1 | Diaryl ureas with kinase inhibiting activity | FLT4, FLT1, FLT3 | KDR 44/4885BRAF 31/4885RAF1 51/4885 |
| US-20070093529-A1 | Diacylhydrazine derivatives | BRAF, RAF1, NRAS | KDR 1543/4885BRAF 1/4885RAF1 2/4885 |
| US-20140329866-A1 | OMEGA-CARBOXYARL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | KDR 456/4885BRAF 1/4885RAF1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.